<DOC>
	<DOCNO>NCT00034242</DOCNO>
	<brief_summary>This study examine whether high-dose intravenous immunoglobulin ( IVIG ) safe effective treat cerebellar ataxia-degeneration cerebellum , part brain responsible coordinate muscle movement balance . The disease cause slowly progressive impairment speech balance , patient often develop slur speech , tremor , clumsiness hand , walk difficulty ( ataxia ) . IVIG derive donate blood purify , clean process form infuse . IVIG immune suppressant routinely use treat neurological condition . Patients 18 year age old hereditary ( genetic ) sporadic ( unknown cause ) cerebellar degeneration may eligible 5-month study . They must evidence immune component condition , gluten sensitivity antiganglioside antibody . Candidates screen neurological examination , review medical record possibly blood test . Participants randomly assign receive infusion either IVIG placebo ( inactive substance ) arm vein month two month . The infusion give hospital dos divide 2 day , last 6 10 hour . Before infusion , patient undergo ataxia assessment test coordination balance may involve finger tap , walk straight line , talk , eye movement . When treatment finish , patient follow clinic month 3 month blood test repeat ataxia assessment evaluate effect treatment .</brief_summary>
	<brief_title>High-Dose Intravenous Immunoglobulin Treat Cerebellar Degeneration</brief_title>
	<detailed_description>There increase evidence antibody mediate , autoimmune component hereditary sporadic cerebellar degeneration . The objective study show clinical improvement stabilization ataxia use treatment intravenous immunoglobulin ( IVIG ) treatment . This study clinical , randomize , placebo-controlled trial IVIG adult patient cerebellar ataxia . Patients select motor control clinic base diagnosis sporadic hereditary cerebellar degeneration . Study drug ( placebo versus active ) give intravenous infusion 2-day period patient hospitalize . This repeat monthly 2 month . Efficacy measurement include clinical ataxia rating scale , motor speed test clinical gait evaluation . These performed baseline , hospitalization , 1 month follow final IVIG infusion . Main outcome measure difference baseline score NINDS ataxia rating scale 1 month follow 2 treatment 2 mg/kg IVIG ( total 4 mg/kg ) .</detailed_description>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>INCLUSION CRITERIA : Adults 18 hereditary sporadic cerebellar degeneration . Sporadic cerebellar degeneration may include cerebellar predominant variant Multiple System Atrophy ( MSAC ) . Hereditary ataxia limit SCAs ( spinocerebellar ataxia ) patient clear autosomal dominant ataxia . Patients must also evidence immune component condition glutensensitivity antiganglioside antibody . EXCLUSION CRITERIA : Patients glutenfree diet . Those wish participate trial must diet period 3 month prior start study . Patients Friedreich 's ataxia . To date , associate autoimmune phenomenon . We would expect population respond . Patients autosomal recessive mitochondrial form ataxia , since autoimmunity study population . Patients hypercoaguable disorder . This include condition like Protein C S deficiency , underlie malignancy and/or paraproteinemia . Patient acute renal insufficiency patient know nephrotoxic drug . Patients selective IgA deficiency Known paraneoplastic cerebellar degeneration . Cerebellar ataxia congenital , static and/or symptomatic ( due stroke , tumor , demyelinate infectious ) . Women pregnant lactating . Those childbearing age ask use effective contraception duration study . Those patient wish use product derive human serum ( example , Jehovah 's Witness ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>Ataxia</keyword>
	<keyword>Treatment</keyword>
	<keyword>IVIG</keyword>
	<keyword>SCA</keyword>
	<keyword>Cerebellar Degeneration</keyword>
	<keyword>Cerebellar Ataxia</keyword>
	<keyword>Cerebellum</keyword>
</DOC>